Optimizing the Care of Patients With Progressive-Fibrosing Interstitial Lung Disease: Applying the Latest Data
Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (e.g., asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss challenging cases on the latest approaches to diagnosing and treating patients with PF-ILD.
Cost: FreeView Offer chevron_right
Free; 1.0 AMA PRA Category 1 Credit(s)™; The My Healio CME Dashboard keeps track of earned credits and saved activities; Personalized recommendations make finding your next activity easy; Over 50,000 of your colleagues know that earn credits is faster and easier with Healio CME
Interstitial lung disease; ILD; Fibrosis; Gastroesophageal relflux; Asbestos; Connective tissue disease; CTD; Systemic sclerosis; SSc; Rheumatoid arthristis; RA; poly-/dermatomyositis; PM/DM; Idiopathic pulmonary fibrosis; IPF; Progressive-fibrosing phentype ILD; PF-ILD
Upon successful completion of this educational activity, participants should be better able to: -Implement treatment strategies for patients with PF-ILD based on the latest clinical evidence. -Evaluate effective multidisciplinary strategies to improve the comprehensive management of patients with PF-ILD.
The intended audience for this activity is pulmonologists, internists, rheumatologists and other health care professionals involved in the management of patients with progressive fibrosing interstitial lung disease (PF-ILD).
Additional credit info
Provider Statement This continuing medical education activity is provided by Vindico Medical Education. Support Statement This activity is supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc. Accreditation Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. This enduring material is approved for 1 year from the date of original release, October 23, 2020 to October 22, 2021.